FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 74 filers reported holding FATE THERAPEUTICS INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,064,941 | -54.4% | 2,389,123 | +2.3% | 0.03% | -53.1% |
| Q2 2023 | $11,115,162 | +45.1% | 2,335,118 | +73.8% | 0.06% | +36.2% |
| Q1 2023 | $7,658,685 | +11682.6% | 1,343,629 | +8143.1% | 0.05% | +4600.0% |
| Q3 2017 | $65,000 | -59.9% | 16,300 | -67.4% | 0.00% | -66.7% |
| Q2 2017 | $162,000 | -41.3% | 50,004 | -17.6% | 0.00% | -50.0% |
| Q1 2017 | $276,000 | +16.9% | 60,704 | -35.4% | 0.01% | +20.0% |
| Q4 2016 | $236,000 | -39.2% | 93,982 | -24.5% | 0.01% | -28.6% |
| Q3 2016 | $388,000 | +27.6% | 124,472 | -30.3% | 0.01% | +16.7% |
| Q2 2016 | $304,000 | -17.4% | 178,647 | -12.6% | 0.01% | -25.0% |
| Q1 2016 | $368,000 | +192.1% | 204,447 | +448.8% | 0.01% | +166.7% |
| Q4 2015 | $126,000 | – | 37,253 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,073,190 | $26,599,000 | 26.59% |
| Polaris Venture Management Co. V, L.L.C. | 1,823,186 | $23,391,000 | 24.97% |
| Casdin Capital, LLC | 2,550,000 | $32,717,000 | 5.60% |
| Redmile Group, LLC | 10,359,666 | $132,915,000 | 5.34% |
| Aquilo Capital Management, LLC | 697,096 | $8,944,000 | 4.33% |
| Eversept Partners, LP | 165,000 | $2,116,950 | 1.15% |
| Artal Group S.A. | 2,150,000 | $27,585,000 | 1.02% |
| AlpInvest Partners B.V. | 26,925 | $345,000 | 0.99% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,654,865 | $21,232,000 | 0.85% |
| Lisanti Capital Growth, LLC | 142,760 | $1,832,000 | 0.74% |